IPI-145

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

IPI-145 ADME and Absolute Bioavailability Study

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)